Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

NCT02523768 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

117

Enrollment

OTHER

Sponsor class

Stopped Difficulties for recruting patients

Conditions

Glomerulonephritis
IgAN

Interventions

DRUG: ATG-F
DRUG: Simulect

Sponsor

Centre Hospitalier Universitaire de Saint Etienne